Literature DB >> 35361410

Essential roles of surgical and pathological evaluations in the management of foreign bodies or inflammatory granulomas mimicking cervical cancer recurrence: A report of two cases.

Min-Hsiang Fang1, Tao-Yeuan Wang2, Jie Lee3, Ya-Ting Jan4, Tze-Chien Chen5.   

Abstract

OBJECTIVE: Positron emission tomography-computed tomography (PET/CT) is an effective modality for evaluating cervical cancer recurrence. We present two cases of suspected recurrent cervical cancer on PET/CT that were pathologically proven to be granulomas. CASE REPORT: Case 1: A 54-year-old woman with FIGO (2009) stage IB1 cervical cancer underwent radical hysterectomy and adjuvant chemoradiotherapy. Case 2: A 44-year-old woman with FIGO (2009) stage IB2 cervical cancer underwent incidental simple hysterectomy with pelvic lymphadenopathy and adjuvant concurrent cisplatin-based chemoradiotherapy. Both patients had peritoneal or pelvic masses with increased 18F-fluorodeoxyglucose (18F-FDG) uptake on PET/CT after 3 years. These masses were finally pathologically proven to be foreign bodies or inflammatory granulomas with abscess, respectively.
CONCLUSION: Foreign bodies or inflammatory granuloma could be one of the differential diagnoses of increased 18F-FDG uptake on PET/CT in patients with cervical cancer after treatment. Pathological evaluation should be considered in these patients to guide further treatment.
Copyright © 2022. Published by Elsevier B.V.

Entities:  

Keywords:  Abdominal abscess; Foreign body granulomas; Uterine cervical cancer

Mesh:

Substances:

Year:  2022        PMID: 35361410     DOI: 10.1016/j.tjog.2022.02.037

Source DB:  PubMed          Journal:  Taiwan J Obstet Gynecol        ISSN: 1028-4559            Impact factor:   1.705


  1 in total

1.  Construction of Nursing Practice Model in Case Management of Concurrent Chemotherapy and Radiochemotherapy Treatment in Cervical Cancer.

Authors:  Liqin Tang; Yan Xing; Hui Li
Journal:  Appl Bionics Biomech       Date:  2022-06-17       Impact factor: 1.664

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.